3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Neoplasms
2
Breast Neoplasms
2
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Leukemia, Myeloid, Acute
1
Gallbladder Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
Gemcitabine
170
130-nm albumin-bound paclitaxel
54
Albumin-Bound Paclitaxel
42
Oxaliplatin
33
Fluorouracil
32
pembrolizumab
30
Capecitabine
30
Leucovorin
28
Irinotecan
28
Radiotherapy
25
Nivolumab
22
Erlotinib Hydrochloride
21
Taxes
19
Cisplatin
19
Bevacizumab
15
Magnetic Resonance Spectroscopy
13
Specimen Handling
12
Radiosurgery
11
Ipilimumab
11
Cyclophosphamide
11
Drug Therapy
10
Carboplatin
10
Biopsy
10
Paclitaxel
9
Docetaxel
9
Cetuximab
9
trametinib
8
olaparib
8
durvalumab
8
Sorafenib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Pancreatic Neoplasms
×
merestinib
×
Clear all
NCT02791334
2024-09-27
PACT
Eli Lilly and Company
Phase 1
Completed
164 enrolled